Cargando…

A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design

The irreversible inhibition of the main protease of SARS-CoV-2 by a Michael acceptor known as N3 has been investigated using multiscale methods. The noncovalent enzyme–inhibitor complex was simulated using classical molecular dynamics techniques and the pose of the inhibitor in the active site was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Guzmán, Carlos A., Ruiz-Pernía, J. Javier, Tuñón, Iñaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179461/
https://www.ncbi.nlm.nih.gov/pubmed/34163622
http://dx.doi.org/10.1039/d0sc04978f
_version_ 1783703786680745984
author Ramos-Guzmán, Carlos A.
Ruiz-Pernía, J. Javier
Tuñón, Iñaki
author_facet Ramos-Guzmán, Carlos A.
Ruiz-Pernía, J. Javier
Tuñón, Iñaki
author_sort Ramos-Guzmán, Carlos A.
collection PubMed
description The irreversible inhibition of the main protease of SARS-CoV-2 by a Michael acceptor known as N3 has been investigated using multiscale methods. The noncovalent enzyme–inhibitor complex was simulated using classical molecular dynamics techniques and the pose of the inhibitor in the active site was compared to that of the natural substrate, a peptide containing the Gln–Ser scissile bond. The formation of the covalent enzyme–inhibitor complex was then simulated using hybrid QM/MM free energy methods. After binding, the reaction mechanism was found to be composed of two steps: (i) the activation of the catalytic dyad (Cys145 and His41) to form an ion pair and (ii) a Michael addition where the attack of the Sγ atom of Cys145 to the Cβ atom of the inhibitor precedes the water-mediated proton transfer from His41 to the Cα atom. The microscopic description of protease inhibition by N3 obtained from our simulations is strongly supported by the excellent agreement between the estimated activation free energy and the value derived from kinetic experiments. Comparison with the acylation reaction of a peptide substrate suggests that N3-based inhibitors could be improved by adding chemical modifications that could facilitate the formation of the catalytic dyad ion pair.
format Online
Article
Text
id pubmed-8179461
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-81794612021-06-22 A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design Ramos-Guzmán, Carlos A. Ruiz-Pernía, J. Javier Tuñón, Iñaki Chem Sci Chemistry The irreversible inhibition of the main protease of SARS-CoV-2 by a Michael acceptor known as N3 has been investigated using multiscale methods. The noncovalent enzyme–inhibitor complex was simulated using classical molecular dynamics techniques and the pose of the inhibitor in the active site was compared to that of the natural substrate, a peptide containing the Gln–Ser scissile bond. The formation of the covalent enzyme–inhibitor complex was then simulated using hybrid QM/MM free energy methods. After binding, the reaction mechanism was found to be composed of two steps: (i) the activation of the catalytic dyad (Cys145 and His41) to form an ion pair and (ii) a Michael addition where the attack of the Sγ atom of Cys145 to the Cβ atom of the inhibitor precedes the water-mediated proton transfer from His41 to the Cα atom. The microscopic description of protease inhibition by N3 obtained from our simulations is strongly supported by the excellent agreement between the estimated activation free energy and the value derived from kinetic experiments. Comparison with the acylation reaction of a peptide substrate suggests that N3-based inhibitors could be improved by adding chemical modifications that could facilitate the formation of the catalytic dyad ion pair. The Royal Society of Chemistry 2021-01-29 /pmc/articles/PMC8179461/ /pubmed/34163622 http://dx.doi.org/10.1039/d0sc04978f Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Ramos-Guzmán, Carlos A.
Ruiz-Pernía, J. Javier
Tuñón, Iñaki
A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
title A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
title_full A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
title_fullStr A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
title_full_unstemmed A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
title_short A microscopic description of SARS-CoV-2 main protease inhibition with Michael acceptors. Strategies for improving inhibitor design
title_sort microscopic description of sars-cov-2 main protease inhibition with michael acceptors. strategies for improving inhibitor design
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179461/
https://www.ncbi.nlm.nih.gov/pubmed/34163622
http://dx.doi.org/10.1039/d0sc04978f
work_keys_str_mv AT ramosguzmancarlosa amicroscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign
AT ruizperniajjavier amicroscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign
AT tunoninaki amicroscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign
AT ramosguzmancarlosa microscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign
AT ruizperniajjavier microscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign
AT tunoninaki microscopicdescriptionofsarscov2mainproteaseinhibitionwithmichaelacceptorsstrategiesforimprovinginhibitordesign